HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Risk-Based Approach “Critical” To Securing Global Supply Chain – FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA wants risk-based draft guidances it published this year to increase industry accountability and free resources for high-risk inspections as the number of foreign-sourced drugs entering the U.S. exceeds the agency's inspection capabilities

You may also be interested in...

Harkin Eyes Inspection Fees For Drug, Ingredient Manufacturers

Sen. Tom Harkin is considering a fee on drug firms to pay for facility inspections.

FDA Foreign Inspections To Double In 2010, Led By Human Drugs And Food

FDA will shoot to double its inspections of foreign facilities in fiscal 2010 to more than 2,000

Top-Down Responsibility Recommended For Import Safety Compliance

Responsibility for ensuring import safety starts at the top of the corporate ladder, FDA says in a draft guidance

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts